Published in Anticancer Drugs on July 01, 2012
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med (2013) 1.62
Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma. PLoS One (2013) 0.94
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer (2014) 0.92
PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. Front Oncol (2013) 0.80
PARP1 Inhibitors: antitumor drug design. Acta Naturae (2015) 0.79
PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. Chin J Cancer Res (2014) 0.79
PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncol Lett (2017) 0.75
PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision. N Z Med J (2007) 1.48
A pilot study of the noninvasive assessment of the lung microbiota as a potential tool for the early diagnosis of ventilator-associated pneumonia. Chest (2015) 1.38
Photoaffinity analogues of farnesyl pyrophosphate transferable by protein farnesyl transferase. J Am Chem Soc (2002) 1.19
Cell-based Assays to Identify Inhibitors of Viral Disease. Expert Opin Drug Discov (2008) 1.11
Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factors. Biochem J (2003) 0.96
Expression and role in glycolysis of human ADP-dependent glucokinase. Mol Cell Biochem (2012) 0.85
GcSTUA, an APSES transcription factor, is required for generation of appressorial turgor pressure and full pathogenicity of Glomerella cingulata. Mol Plant Microbe Interact (2007) 0.84
Simultaneous on-chip DC dielectrophoretic cell separation and quantitative separation performance characterization. Anal Chem (2012) 0.84
Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs (2007) 0.84
A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden. Am J Hum Genet (2013) 0.84
Identification of ryanodine receptor 1 single-nucleotide polymorphisms by high-resolution melting using the LightCycler 480 System. Anal Biochem (2007) 0.83
Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions. BMC Mol Biol (2007) 0.82
Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA. Anesthesiology (2010) 0.81
Metabolite profiling and quantification of phytochemicals in potato extracts using ultra-high-performance liquid chromatography-mass spectrometry. J Sci Food Agric (2013) 0.80
Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia. Orphanet J Rare Dis (2010) 0.80
Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1. Anticancer Drugs (2004) 0.80
Non-invasive detection of pulmonary pathogens in ventilator-circuit filters by PCR. Am J Transl Res (2012) 0.79
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines. Oncol Res (2004) 0.79
Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells. Anesthesiology (2013) 0.78
Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology (2008) 0.78
Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia. Anesth Analg (2014) 0.76
Esophageal stents in malignant dysphagia: a two-edged sword? J Palliat Care (2004) 0.75
Quantification of DNA by agarose gel electrophoresis and analysis of the topoisomers of plasmid and M13 DNA following treatment with a restriction endonuclease or DNA topoisomerase I. Biochem Mol Biol Educ (2005) 0.75